119 related articles for article (PubMed ID: 2702665)
1. Interactions of the phenylpyrazolo steroid cortivazol with glucocorticoid receptors in steroid-sensitive and -resistant human leukemic cells.
Thompson EB; Srivastava D; Johnson BH
Cancer Res; 1989 Apr; 49(8 Suppl):2253s-2258s. PubMed ID: 2702665
[TBL] [Abstract][Full Text] [Related]
2. Two glucocorticoid binding sites on the human glucocorticoid receptor.
Srivastava D; Thompson EB
Endocrinology; 1990 Oct; 127(4):1770-8. PubMed ID: 2205477
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two structurally diverse glucocorticoid receptor agonists: cortivazol selectively regulates a distinct set of genes separate from dexamethasone in CEM cells.
Miller AL; Webb MS; Thompson EB
Steroids; 2007 Sep; 72(9-10):673-81. PubMed ID: 17606285
[TBL] [Abstract][Full Text] [Related]
4. Cortivazol mediated induction of glucocorticoid receptor messenger ribonucleic acid in wild-type and dexamethasone-resistant human leukemic (CEM) cells.
Ashraf J; Kunapuli S; Chilton D; Thompson EB
J Steroid Biochem Mol Biol; 1991 May; 38(5):561-8. PubMed ID: 2039752
[TBL] [Abstract][Full Text] [Related]
5. [3H]cortivazol: a unique high affinity ligand for the glucocorticoid receptor.
Schlechte JA; Simons SS; Lewis DA; Thompson EB
Endocrinology; 1985 Oct; 117(4):1355-62. PubMed ID: 4029081
[TBL] [Abstract][Full Text] [Related]
6. Use of [3H]cortivazol to characterize glucocorticoid receptors in a dexamethasone-resistant human leukemic cell line.
Schlechte JA; Schmidt TJ
J Clin Endocrinol Metab; 1987 Mar; 64(3):441-6. PubMed ID: 2880860
[TBL] [Abstract][Full Text] [Related]
7. Glucocorticoids in malignant lymphoid cells: gene regulation and the minimum receptor fragment for lysis.
Thompson EB; Nazareth LV; Thulasi R; Ashraf J; Harbour D; Johnson BH
J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):273-82. PubMed ID: 1314075
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoid-resistant human acute lymphoblastic leukemic cell line with functional receptor.
Zawydiwski R; Harmon JM; Thompson EB
Cancer Res; 1983 Aug; 43(8):3865-73. PubMed ID: 6134583
[TBL] [Abstract][Full Text] [Related]
9. Binding studies of RU486 in different Reuber hepatoma variants.
Chasserot-Golaz S; Beck G
Receptor; 1993; 3(1):31-7. PubMed ID: 8348081
[TBL] [Abstract][Full Text] [Related]
10. Glucocorticoid versus antiglucocorticoid activity: can a single functional group modification of glucocorticoid steroids always convey antiglucocorticoid activity?
Lamontagne N; Mercier L; Pons M; Thompson EB; Simons SS
Endocrinology; 1984 Jun; 114(6):2252-63. PubMed ID: 6547091
[TBL] [Abstract][Full Text] [Related]
11. Non-glucocorticoid receptor-mediated effects of the potent glucocorticoid deacylcortivazol.
Harmon JM; Schmidt TJ; Thompson EB
Cancer Res; 1982 Jun; 42(6):2110-4. PubMed ID: 6951631
[TBL] [Abstract][Full Text] [Related]
12. The distinct agonistic properties of the phenylpyrazolosteroid cortivazol reveal interdomain communication within the glucocorticoid receptor.
Yoshikawa N; Yamamoto K; Shimizu N; Yamada S; Morimoto C; Tanaka H
Mol Endocrinol; 2005 May; 19(5):1110-24. PubMed ID: 15677712
[TBL] [Abstract][Full Text] [Related]
13. Distinct interaction of cortivazol with the ligand binding domain confers glucocorticoid receptor specificity: cortivazol is a specific ligand for the glucocorticoid receptor.
Yoshikawa N; Makino Y; Okamoto K; Morimoto C; Makino I; Tanaka H
J Biol Chem; 2002 Feb; 277(7):5529-40. PubMed ID: 11741935
[TBL] [Abstract][Full Text] [Related]
14. Cloning and expression of mutant glucocorticoid receptors from glucocorticoid-sensitive and -resistant human leukemic cells.
Powers JH; Hillmann AG; Tang DC; Harmon JM
Cancer Res; 1993 Sep; 53(17):4059-65. PubMed ID: 8358735
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxicity of cortivazol in childhood acute lymphoblastic leukemia.
Styczynski J; Kurylak A; Wysocki M
Anticancer Res; 2005; 25(3B):2253-8. PubMed ID: 16158972
[TBL] [Abstract][Full Text] [Related]
16. High affinity binding and regulatory actions of dexamethasone-type I receptor complexes in mouse brain.
Luttge WG; Davda MM; Rupp ME; Kang CG
Endocrinology; 1989 Sep; 125(3):1194-203. PubMed ID: 2759022
[TBL] [Abstract][Full Text] [Related]
17. Glucocorticoid receptors in human leukemias and related diseases.
Thompson EB; Smith JR; Bourgeois S; Harmon JM
Klin Wochenschr; 1985 Aug; 63(15):689-98. PubMed ID: 2413243
[TBL] [Abstract][Full Text] [Related]
18. Resistance of human leukemic CEM-C1 cells is overcome by synergism between glucocorticoid and protein kinase A pathways: correlation with c-Myc suppression.
Medh RD; Saeed MF; Johnson BH; Thompson EB
Cancer Res; 1998 Aug; 58(16):3684-93. PubMed ID: 9721879
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoid-receptor-gene defects and resistance to glucocorticoid-induced apoptosis in human leukemic cell lines.
Hala M; Hartmann BL; Böck G; Geley S; Kofler R
Int J Cancer; 1996 Nov; 68(5):663-8. PubMed ID: 8938150
[TBL] [Abstract][Full Text] [Related]
20. Identification of the activation-labile gene: a single point mutation in the human glucocorticoid receptor presents as two distinct receptor phenotypes.
Ashraf J; Thompson EB
Mol Endocrinol; 1993 May; 7(5):631-42. PubMed ID: 8316249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
